Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : LM-030
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
LifeMax Receives Fast Track Designation For LM-030 for the Treatment of Netherton Syndrome
Details : LM-030 is the only program in clinical development for Netherton and could potentially become the first approved targeted therapy.
Product Name : LM-030
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 14, 2020
Lead Product(s) : LM-030
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
